Güldütuna S, Deisinger B, Weiss A, Freisleben H J, Zimmer G, Sipos P, Leuschner U
Department of Gastroenterology, Center of Internal Medicine, University Clinics Frankfurt, Frankfurt am Main, Germany.
Biochim Biophys Acta. 1997 Jun 12;1326(2):265-74. doi: 10.1016/s0005-2736(97)00030-8.
Ursodeoxycholate is used to treat primary biliary cirrhosis and is incorporated into hepatocyte plasma membranes. Its steroid nucleus binds to the apolar domain of the membrane, in a similar position to cholesterol. Therefore the question arises whether ursodeoxycholate has a similar effect on membrane structure and stability as cholesterol. Using differential scanning calorimetry the thermotropic behavior of egg phosphatidylcholine and dimyristoylphosphatidylcholine were studied after incubation with cholesterol or ursodeoxycholate. Large unilamellar vesicles were prepared with cholesterol contents of 0-50%. Following incubation of these vesicles with different amounts of ursodeoxycholate, vesicle stability in a gravitational field was investigated by measuring the phospholipid and cholesterol release. Vesicle size was studied by laser light scattering after incubation with cheno- and ursodeoxycholate, and the release of entrapped carboxyfluorescein was measured by means of fluorescence spectroscopy. Increasing cholesterol diminished the enthalpy of the phase transition in the membrane. Ursodeoxycholate decreased the enthalpy of the phase transition at even lower concentrations. Lipid release from vesicles in a high gravitational field diminished with increasing cholesterol content of the vesicles. Ursodeoxycholate had a comparable effect, which increased as the cholesterol content of the vesicles was decreased. Chenodeoxycholate damaged vesicles, whereas ursodeoxycholate did not. Cholesterol and ursodeoxycholate (below its critical micellar concentration) decreased the carboxyfluorescein release from vesicles induced by chenodeoxycholate. Thus like cholesterol, ursodeoxycholate is incorporated into phospholipid model membranes and reduces the change in enthalpy of the gel to liquid-crystalline phase transition. Like cholesterol ursodeoxycholate also maintains membrane stability and prevents membrane damage induced by mechanical and chemical stress.
熊去氧胆酸用于治疗原发性胆汁性肝硬化,并被整合到肝细胞质膜中。其甾体核与膜的非极性区域结合,位置与胆固醇相似。因此,问题在于熊去氧胆酸对膜结构和稳定性的影响是否与胆固醇相似。使用差示扫描量热法研究了胆固醇或熊去氧胆酸孵育后鸡蛋磷脂酰胆碱和二肉豆蔻酰磷脂酰胆碱的热致行为。制备了胆固醇含量为0 - 50%的大单层囊泡。用不同量的熊去氧胆酸孵育这些囊泡后,通过测量磷脂和胆固醇释放来研究囊泡在重力场中的稳定性。用鹅去氧胆酸和熊去氧胆酸孵育后,通过激光散射研究囊泡大小,并通过荧光光谱法测量包封的羧基荧光素的释放。胆固醇含量增加会降低膜相变的焓。熊去氧胆酸在更低浓度下就会降低相变的焓。随着囊泡胆固醇含量的增加,高重力场中囊泡的脂质释放减少。熊去氧胆酸有类似的作用,且随着囊泡胆固醇含量的降低而增强。鹅去氧胆酸会破坏囊泡,而熊去氧胆酸不会。胆固醇和熊去氧胆酸(低于其临界胶束浓度)会减少鹅去氧胆酸诱导的囊泡中羧基荧光素的释放。因此,与胆固醇一样,熊去氧胆酸也能整合到磷脂模型膜中,并减少凝胶到液晶相变的焓变。与胆固醇一样,熊去氧胆酸还能维持膜的稳定性,并防止机械和化学应激诱导的膜损伤。